XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2022
May 31, 2022
Aug. 31, 2021
May 31, 2021
Aug. 31, 2022
Aug. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES            
Net loss $ (215,918) $ (231,737) $ (224,718) $ (316,283) $ (447,655) $ (541,001)
Adjustments to reconcile net loss to net cash used by operating activities:            
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.         306,277 386,329
Changes in operating assets and liabilities            
Prepaids         879 (42)
Accounts payable         1,935 (13,252)
Accrued liabilities         9,914 (3,876)
NET CASH USED BY OPERATING ACTIVITIES         (128,650) (171,842)
CASH FLOWS FROM FINANCING ACTIVITIES            
Contribution of capital         126,534 172,684
NET CASH PROVIDED BY FINANCING ACTIVITIES         126,534 172,684
NET INCREASE (DECREASE) IN CASH         (2,116) 842
CASH AT BEGINNING OF PERIOD   $ 3,382   $ 62 3,382 62
CASH AT END OF PERIOD $ 1,266   $ 904   $ 1,266 $ 904